en
Feedback
Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Open in Telegram

NVIDIA inception Member, Nebius AI Discovery Awards semifinalist Potentially first $1T Longevity BioTech AI company Part of Longevity Ecosystem LongevityInTime.com @PickleballPartners Shop https://web.tribute.tg/l/lr Homes www.Africa.Villas

Show more
1 069
Subscribers
No data24 hours
+37 days
-1830 days
Attracting Subscribers
September '26
September '26
+8
in 0 channels
August '26
+20
in 0 channels
Get PRO
July '26
+13
in 0 channels
Get PRO
June '26
+14
in 0 channels
Get PRO
May '26
+34
in 0 channels
Get PRO
April '26
+36
in 0 channels
Get PRO
March '26
+14
in 0 channels
Get PRO
February '26
+14
in 0 channels
Get PRO
January '26
+15
in 0 channels
Get PRO
December '25
+12
in 0 channels
Get PRO
November '25
+14
in 0 channels
Get PRO
October '25
+18
in 0 channels
Get PRO
September '25
+21
in 0 channels
Get PRO
August '25
+32
in 0 channels
Get PRO
July '25
+114
in 0 channels
Get PRO
June '25
+9
in 0 channels
Get PRO
May '25
+6
in 0 channels
Get PRO
April '25
+5
in 0 channels
Get PRO
March '25
+9
in 0 channels
Get PRO
February '25
+9
in 0 channels
Get PRO
January '25
+20
in 0 channels
Get PRO
December '24
+14
in 0 channels
Get PRO
November '24
+8
in 0 channels
Get PRO
October '24
+7
in 0 channels
Get PRO
September '24
+9
in 0 channels
Get PRO
August '24
+10
in 0 channels
Get PRO
July '24
+15
in 0 channels
Get PRO
June '24
+16
in 0 channels
Get PRO
May '24
+13
in 0 channels
Get PRO
April '24
+10
in 0 channels
Get PRO
March '24
+13
in 0 channels
Get PRO
February '24
+17
in 0 channels
Get PRO
January '24
+14
in 0 channels
Get PRO
December '23
+14
in 0 channels
Get PRO
November '23
+10
in 0 channels
Get PRO
October '23
+8
in 0 channels
Get PRO
September '23
+14
in 0 channels
Get PRO
August '23
+24
in 0 channels
Get PRO
July '23
+7
in 0 channels
Get PRO
June '23
+9
in 0 channels
Get PRO
May '23
+10
in 0 channels
Get PRO
April '23
+14
in 0 channels
Get PRO
March '23
+22
in 0 channels
Get PRO
February '23
+20
in 0 channels
Get PRO
January '23
+7
in 0 channels
Get PRO
December '22
+6
in 0 channels
Get PRO
November '22
+17
in 0 channels
Get PRO
October '22
+17
in 0 channels
Get PRO
September '22
+9
in 0 channels
Get PRO
August '22
+11
in 0 channels
Get PRO
July '22
+2
in 0 channels
Get PRO
June '22
+1
in 0 channels
Get PRO
May '22
+3
in 0 channels
Get PRO
April '22
+8
in 0 channels
Get PRO
March '22
+4
in 0 channels
Get PRO
February '220
in 0 channels
Get PRO
January '220
in 0 channels
Get PRO
December '210
in 0 channels
Get PRO
November '210
in 0 channels
Get PRO
October '210
in 0 channels
Get PRO
September '210
in 0 channels
Get PRO
August '210
in 0 channels
Get PRO
July '210
in 0 channels
Get PRO
June '21
+73
in 0 channels
Get PRO
May '21
+13 445
in 0 channels
Get PRO
April '21
+10 157
in 0 channels
Get PRO
March '21
+18 260
in 0 channels
Get PRO
February '21
+41 397
in 0 channels
Date
Subscriber Growth
Mentions
Channels
19 September0
18 September0
17 September+1
16 September+1
15 September0
14 September+1
13 September+2
12 September+1
11 September0
10 September0
09 September0
08 September+1
07 September0
06 September+1
05 September0
04 September0
03 September0
02 September0
01 September0
Channel Posts
Food and anti-parasitic treatment slow epigenetic aging in wild mice Scientists experimentally tested on wild woodland mice that feeding and anti‑parasite treatment slow the epigenetic clocks that measure aging via DNA methylation marks. A team from Edinburgh and Altos Labs built DNA‑methylation clocks for the woodland mouse and transferred them to a wild population near Edinburgh. In the September 16 version of the study, mice that were simultaneously fed and treated for intestinal parasites showed a significantly slower clock rate than untreated animals of the same chronological age. Wild animals’ ages are rarely known precisely because they are not caught at birth; body mass, tooth wear or telomere length give only rough estimates or require killing the animal. Epigenetic clocks solve this: with age, methylation changes at specific DNA sites predict age. Sarah Wolf and colleagues first trained the clocks on 74 laboratory woodland mice of known age using 177 such marks. The clocks predicted age with an error of 5.45 days on the training set and 14.64 days on independent validation. This is an order of magnitude more accurate than universal pan‑mammalian clocks trained on 18 🔗 Read original →

2
Karl Pfleger argues aging therapies should be judged by multi‑disease benefit, not lifespan On 18 September 2026, investor Karl Pfleger responded to Professor João Pedro de Magalhães’ question about how to judge anti‑aging therapies if not by lifespan. Pfleger proposed an alternative criterion and noted that the only organization testing such combinations in practice, the LEV Foundation, ran an experiment where two of three approaches failed and a larger follow‑up remains unfunded due to lack of money. On 9 August 2026, de Magalhães wrote that humanity is not approaching victory over aging, citing that over the past century the only reliable way to extend mouse lifespan has been caloric restriction. Pfleger replied on 10 August that measuring progress by a single best therapy is mistaken, because aging comprises at least seven distinct molecular breakdowns—such as senescent‑cell accumulation—that require different treatments, just as different cancers need different drugs. On the same day, de Magalhães disagreed, insisting lifespan remains the only reliable metric; otherwise symptomatic relief could be mistaken for anti‑aging effect. On 7 September Pfleger countered with an analogy to the 1960 Moon landing, arguing that demanding immediate success ignores the needed development time. On 17 September de Magalhães acknowledged the need for combination therapies but asked how to prove they work—or don’t. The next day Pfleger answered: a therapy validates the “geroscience hypothesis” if it treats, alleviates, or prevents several age‑related diseases at once, even if it does not extend life. Individual interventions may show no effect alone; benefit appears only when combined. He cited the LEV Foundation’s RMR1 experiment on 1,000 mice, which showed a single dose of repair does not last longer than one year. Of the three interventions, two were defective—one “broken,” the other “partially broken.” A second, larger trial with eight interventions still seeks funding. Pfleger lamented that only one group is testing such combinations, calling it regrettable, and noted that structural incentives discou 🔗 Read original →
4
3
ByteDance closed the first external funding round for its AI‑driven drug spin‑off Anew Labs on September 16, 2026, securing $290 million at a $1.5 billion valuation, according to Reuters. The round was led by HSG (formerly 🔗 Read original →
5
4
Longeveron’s stem‑cell therapy fails in infant heart trial, shares plunge On 16 September Longeveron announced that its cell therapy laromeestrocel did not improve heart function in the phase 2b ELPIS II trial of infants with hypoplastic left heart syndrome. The difference in right‑ventricular ejection fraction after 12 months was –0.7 percentage points, which was not statistically significant. The news sent the stock down 59% the following day, and it kept falling to close at $2.49 on 18 September, giving the company a market value of about $7.9 million. Longeveron said its cash reserves, reported on 12 August, would last only until the end of the year. Despite the setback, the company highlighted a 31% reduction in cardiovascular events and a 63.4‑meter gain in a six‑minute walk test from its frailty program, and noted that laromeestrocel remains in the XPRIZE Healthspan finals with a $1 million award. Longeveron is now reviewing strategic options and seeking new investors to keep the frailty program alive. 🔗 Read original →
4
5
Splice-site disruption extends progeric mouse lifespan 2.4‑fold and restores fertility On 18 September a preprint from the lab of Zhongjun Zhou at Hong Kong University appeared on bioRxiv, 18 September. The researchers used CRISPR‑Cas9 not to correct the LMNA mutation that causes Hutchinson‑Gilford progeria but to destroy the nearby splice‑site signal that the mutation hyper‑activates. By cutting the DNA at the splice‑site anchor, the guide RNA preferentially hits the mutant allele and breaks the donor site, which is enough to abolish the aberrant splicing. In patient fibroblasts this reduced progerin production by **92 🔗 Read original →
8
6
Seven drug targets identified for sarcopenia as first myostatin blocker gains FDA approval A review published in Nature Reviews Drug Discovery on 7 September 2026 mapped seven pharmacological mechanisms against sarcopenia, the age‑related loss of muscle mass and strength that currently has no approved drugs. Four days later, on 11 September, the FDA approved apitegromab from Scholar Rock, the first‑ever myostatin‑blocking drug, for spinal muscular atrophy. In the same week, trial data showed that apitegromab combined with tirzepatide almost halved muscle loss during weight loss, and the EMBRAZE study found the pair preserved 54.9% more muscle mass than tirzepatide alone over 24 weeks. Sarcopenia is a distinct diagnosis: after age 50 people lose about 10% per decade of muscle, and between 40 and 80 years the loss ranges from one‑third to one‑half. The diagnostic code appeared in 2016 and the clinical definition in 2019, without which there were no insurance coverage or trial criteria. The review highlights seven independent mechanisms, including declining cellular energy, exhausted stem cells (which drop 24% in women and 37% in men with age, two‑thirds of the remaining cells being poorly functional), loss of nerve‑muscle connections, and vascular inflammation. It also notes the enzyme 15‑PGDH as a “gerozyme” whose inhibition in old mice rejuvenated muscle, intestine, kidney, lung and even memory, and that blocking it restored exercise‑induced muscle growth, boosting strength nearly 50% above untreated animals. 🔗 Read original →
7
7
Dreaming of a Rationalist-Transhumanist Hearts of Iron 4 Mod Generally, I dream of a mod for Hearts of Iron 4 built around transforming countries into rationalist-transhumanist societies. It would focus on modeling technological competition. 🔗 Source: @solid_state_humanity
8
8
Sex differences in immune aging revealed in uncastrated beagles On 15 September a group from the Southern University of Science and Technology in Shenzhen and co‑authors posted a preprint on bioRxiv. They examined 80 uncastrated laboratory beagles aged 1–11 years and found that age‑related immune remodeling strongly depended on sex. In both sexes leukocyte numbers declined with age, but in the oldest geriatric subgroup some markers rose again, showing non‑linear blood aging. Cytokine patterns diverged sharply: males showed significant changes in 9 of 40 cytokines (most increasing with age then falling in deep old age), whereas females changed only 2 of the same 40. Similar sex‑dependent shifts appeared for several erythrocytic traits, such as hemoglobin, but not for total leukocyte count. Dogs share our environment and age‑related diseases while aging faster, making them useful models. However, most companion dogs are neutered, and sex hormones—major regulators of immune cells—mask natural sex differences in those cohorts. By studying uncastrated beagles the authors could observe the underlying divergence. The classic view of immune aging as a single linear process common to all was contradicted; the data formed two distinct curves depending on sex. In humans, immune aging is also more heritable in men than in women. To test whether interventions reveal the same sex specificity, the same team treated a separate group of 24 young beagles for 90 days with rapamycin, canagliflozin, or calorie restriction. Rapamycin produced the broadest response: leukocyte and neutrophil counts rose, while GM‑CSF, IL‑10, MCP‑1 and TNF‑α fell, yet four other cytokines increased, indicating simultaneous suppression and activation of immune signals. Canagliflozin, chosen because it extended male mouse lifespan by 14% but not female, caused weight loss in males already in the first month and in females 🔗 Read original →
9
9
Proteasome stress reveals a common molecular signature of aging 🔗 Read original →
10
10
Naked mole‑rat microglia hoard fat, shielding the brain from aging The naked mole‑rat, a mouse‑sized rodent with an almost non‑aging brain and a lifespan of ~40 years, shows almost no typical age‑related diseases such as cancer, cardiovascular illness, or neurodegeneration. 🔗 Read original →
8
11
Proteomic map reveals stepwise collapse of protein quality control in human cell senescence Scientists at the Institute of Molecular Biology in Mainz used mass spectrometry to track how the protein makeup of human IMR90 lung fibroblasts changes across four sequential aging stages of replicative senescence, measuring 5923 proteins per stage. The work was published 16 September in Nature Communications. They found that nuclear and chromatin proteins are lost first, while DNA‑replication proteins and one histone variant persist longest. About 10% of the changing proteins behave opposite to their RNA levels — accumulating transcripts but disappearing as proteins — a pattern also seen in the brain of the killifish, a model of aging. The most striking change concerns the cell’s cleanup systems: despite more protein debris, autophagy speed and proteasome 🔗 Read original →
6
12
Frailty Index for House Crickets Shows Rapamycin Reduces Age‑Related Decline On Sep 17 the lab of geropathologist Warren Ladiges at the University of Washington published a frailty index for the house cricket *Acheta domesticus* in npj Aging, September 17. It is the first quantitative measure of functional aging for this species. The index combines ten video‑tracked behavioral parameters, each scored 0–4 and summed to a total frailty score from 0 to 1, with higher values indicating greater decline. In young (4–6 weeks) and old (10–12 weeks) crickets the score rose similarly for both sexes, from 0.38 to 0.65 in females and from 0.38 to 0.67 in males. To test the index, middle‑aged crickets (8 weeks) were fed rapamycin, acarbose or phenylbutyrate for two weeks using doses from the NIA’s Interventions Testing Program. By 10 weeks the frailty index of the rapamycin group had dropped nearly half relative to controls in both sexes, whereas acarbose and phenylbutyrate showed no significant effect. In humans frailty is a state distinct from chronological age that reflects loss of physiological reserves and predicts risk better than years lived; geriatrics assess it by summing deficits across aging traits. The authors applied the same logic to crickets, creating a tool analogous to a clinical frailty index. The index is intended as a cheap, fast first screen for geroprotector candidates such as metformin, SGLT2 🔗 Read original →
6
13
Mitochondrial Complex I vs IV Damage Extends Worm Life via Distinct Pathways, Metformin Effects Differ Mahidol University & Ghent University preprint, September 17 Researchers compared the effects of knocking down Complex I (nuo‑6) and Complex IV (cco‑1) in *C. elegans*. Inhibition of Complex I raised median lifespan from 17→19 days, while Complex IV inhibition extended it further to 24 days. Both knockdowns activated the mitochondrial unfolded‑protein response (UPRmt) via ATFS‑1, but the downstream requirements diverged. Loss of ATFS‑1 collapsed the Complex I benefit to 15 days (below control), whereas Complex IV worms retained a 24‑day median despite lost chaperone production. The AMPK homolog AAK‑2 showed mirror‑image effects: its removal slightly boosted Complex I longevity to 21 days, but knocked Complex IV lifespan down to about 15 days. Metformin, which inhibits Complex I and activates AAK‑2, added a second hit to Complex I/AAK‑2 worms, dropping median from 21→18 days, yet it markedly prolonged Complex IV worms from 24→30 days and even rescued AAK‑2‑deficient IV worms from 15→20 days. These findings reconcile earlier contradictory reports: ATFS‑1 was deemed essential for Complex I‑driven longevity in 2018, while 2014 showed Complex IV worms lived long without ATFS‑1. The new work shows both are correct, acting on different respiratory‑chain nodes, and suggests that drugs like metformin must be tested separately for each complex. 🔗 Read original →
8
14
New Model Links Brain Aging to Disrupted DNA Repair Rhythm and TyrRS Switch A theoretical model published 17 September in GeroScience ties together two hallmarks of brain aging: the buildup of DNA damage in neurons and the weakening of circadian rhythms. The authors propose the enzyme tyrosyl‑tRNA synthetase (TyrRS) as a molecular switch that coordinates both processes and explain why they falter together in aging and Alzheimer’s disease. TyrRS normally charges tyrosine onto tRNA for protein synthesis, but when free tyrosine is low — during the night or fasting — a fraction translocates to the nucleus. There it activates PARP1 to detect DNA breaks, keeps transposable‑element DNA silenced to prevent inflammation, and induces the LIN9 gene. LIN9 joins the DREAM complex, which by day represses 67 DNA‑repair genes (including BRCA1) and releases them at night for repair. The oscillation amplitude of these three activities matters more than their average level. With age, blood tyrosine rises 15–25%, narrowing the nighttime window for TyrRS action, while suprachiasmatic‑nucleus neuron loss dampens circadian rhythms. Together they lock the cascade in an intermediate state — still active but no longer swinging between peak and trough. Because the rhythm flattens, Alzheimer’s tissue shows elevated average DREAM activity, which was read as stronger repression of DNA repair. The model argues this reflects a lost oscillation, not deeper suppression. Consequently, drugs with constant release would further blunt the needed swing; a short dose timed to the sleep phase is preferable. Internal time can be measured with the HairTime test, which reads 17 clock genes from a single plucked hair. The framework aligns with Nedergaard’s findings that sleep‑driven cerebrospinal fluid flow clears amyloid and tau, explaining why lecanemab and donanemab give only modest cognitive gains. If the DNA‑repair clock is broken, 🔗 Read original →
12
15
Open LongevityBench Shows Compact AI Models Outperform Closed Giants on Aging Data Insilico Medicine and Liquid AI released the open‑access LongevityBench aging benchmark in Cell, accompanied by five compact models and the Longevity Claw tool; co‑author Vadim Gladyshev of Harvard Medical School contributed to the work. Previous aging clocks rely on a single data type, but the MMAI Gym for Science platform showed that a language model fine‑tuned on structured data can handle drug discovery, prompting the team to treat all aging measurements as text for a unified model. LongevityBench comprises 17 tasks spanning five biological data layers — clinical records, genetics, DNA methylation, blood proteins, and more — with 25,457 assignments programmatically assembled from raw measurements so answers cannot be memorized from training text. Testing 18 commercial models from OpenAI, Google, Anthropic, xAI, DeepSeek and Moonshot AI found Gemini 3.1 Pro leading but not statistically distinct from four others; after fine‑tuning five open models ranging from 0.6 – 9 billion parameters on aging data, the 9‑billion L‑Qwen3.5 secured first place with a confidence interval that did not overlap any commercial rival, while the 0.6‑billion version ranked sixth out of 26, surpassing Claude Opus 4.5, Kimi K2.5, GPT‑5.2 and Grok 4.3. A control test on published aging facts favored large universal models, indicating the compact models win through raw‑data reasoning rather than memorization; sensitivity analysis revealed that deleting the NHANES blood‑analysis block altered 47.4% of correct answers, proving reliance on real biomarkers. 🔗 Read original →
8
16
APOE4 Increases Vulnerability to Oxidative and Metabolic Stress in Fruit Flies Researchers at Texas A&M University substituted the fly’s lipid‑transport gene GLaz with either the human APOE3 or APOE4 allele. On standard food, flies carrying **APOE4 🔗 Read original →
7
17
AI Model Detects Rare Genetic Diseases Years Before Diagnosis Researchers from MyOme and the Mayo Clinic released a preprint describing a model that reads electronic health records as a chronological timeline of findings. In nearly 3 million patients the model identified signs of ten rare genetic diseases. A separate validation on 143 patients with long undiagnosed histories showed the model flagged disease before diagnosis, with a median lead time of 1.9–21.7 years. One Fabry patient, for example, endured years of limb pain, abdominal discomfort, and skin rashes before anyone connected the symptoms. On average, the diagnostic odyssey for a rare disease lasts **4–8 🔗 Read original →
8
18
FDA‑approved Friedreich’s ataxia drug found to degrade STING protein Scientists at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, showed that omaveloxolone — the FDA‑approved treatment for Friedreich’s ataxia since 2023 — binds the STING protein and triggers its cellular destruction. By preventing STING from closing, the drug exposes hydrophobic regions, lowers its melting temperature, and flags it for ubiquitination by HUWE1, leading to proteasomal degradation. At a concentration of 118 nM, cellular STING levels drop by about half; a slightly higher dose reduces STING by ≈99 %. In aged mice this depletion quelled chronic tissue inflammation that had persisted for years, without affecting body weight over two months of twice‑weekly injections. The drug also activates NRF2 via KEAP1 independently of STING, a mechanism that remains functional even when STING is genetically knocked out. Thus omaveloxolone operates through two distinct pathways: STING degradation drives the primary anti‑inflammatory effect, while NRF2 activation contributes additional cellular protection. The study was published in Nature Communications, 17 September 2026. Prior to this work, omaveloxolone’s only known target was KEAP1/NRF2, and no approved drug had directly acted on STING — experimental inhibitors such as H‑151 only blocked signaling without degrading the protein. Because omaveloxolone has already undergone clinical trials and accumulated over three years of safety data in Friedreich’s ataxia patients, its repurposing for age‑related inflammation could proceed rapidly to clinical testing. 🔗 Read original →
8
19
US Gerontologists Propose 12 Molecular Signals to Spot Real Anti‑Aging Drugs On 17 September Stephen Osted, Richard Miller and Matt Kaberlein published their analysis in Frontiers in Science. They reviewed data from the federal Interventions Testing Program (ITP), which Miller helps lead, to identify common molecular shifts in mouse models that already show slowed aging. Proving that a compound slows aging in mice currently costs $100–300 000 and takes 3–4 years; ITP can test only a small fraction of candidates, and roughly 15 % of those tested extend lifespan. The team sought a filter — a set of parameters that deviate from the norm in as many of these models as possible, regardless of the direction of change. This effort yielded 12 molecular signals that serve as a “speedometer” for aging, unlike epigenetic clocks, which act as an odometer requiring years‑spaced measurements. The signals include increased hippocampal BDNF and doublecortin, both neuroprotective and pro‑neurogenic. Of the twelve, only irisin and GPLD1 are presently measurable in blood; the rest require tissue from liver, fat, brain or muscle. A computational model built by Miller on 1051 plasma features from ITP mice correctly predicted lifespan gains for five hidden interventions. The strongest ITP result is the rapamycin + acarbose combination: it raised median lifespan by 29 % in males and 22 % in females, while rapamycin alone gave 23 % (males) and 26 % (females). Looking ahead, the authors propose validation in dogs — the Dog Aging Project already tracks >50 000 pets testing rapamycin — followed by repeat blood sampling in humans aged 55–60 at ten‑year intervals to find circulating predictors of future change. Kaberlein stresses that the main hurdle in translating aging biology to better health is knowing whether an intervention truly alters aging speed; practical biomarkers would answer this without waiting years for lifespan effects. Osted notes that many mouse geroprotectors remain fully effective when started in late adulthood, suggesting similar therapies could benefit middle‑aged people. The authors argue that the traditional “hallmarks of aging” list is a subjective construct that funnels funding toward convenient topics, and they view cellular senescence as overstated — long‑telomere mice and dogs show aging indistinguishable from short‑telomere humans. They label the field’s reluctance “gerontophobia,” a fear of studying aging slowing rather than treating its diseases. Their calculations show that eliminating all cancers after age 50 would raise human median lifespan only 2–3 %, an order of magnitude less than the lifespan boost seen in mice from rapamycin + acarbose. 🔗 Read original →
7
20
Jennifer Doudna’s Lab Discovers VIPR, a Viral Ancestor of CRISPR Jennifer Doudna’s lab at the University of California, Berkeley announced the discovery of VIPR – a family of viral proteins that are likely evolutionary precursors of CRISPR‑Cas. The findings appeared in two papers published Science on 17 September 2026. VIPR 🔗 Read original →
9